The sharp narrowing of net loss combined with accelerating prescription growth for AUVELITY in the Alzheimer's agitation indication suggests the company is approaching cash flow positivity faster than expected. Key catalysts to watch: ENGAGE Phase 3 topline results in Q1 2027 and AXS-12 PDUFA date on May 1, 2027.
Drugs in focus
AXSM drug pipeline →AXS-12
● Neutral Named in this 8-K- Impact
- Phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
- Next catalyst
- PDUFA date · May 1, 2027 165d
What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
Price Chart
Executive Summary
Axsome reported Q3 2026 net product revenue of $259.7M (+52% YoY), driven by AUVELITY sales of $207.6M (+53% YoY) and SUNOSI revenue of $48.2M (+47% YoY). Net loss narrowed sharply to $12.9M ($0.25 per share) from $47.2M ($0.94 per share) a year ago, as revenue growth outpaced SG&A expense increases. The company also posted an updated corporate presentation highlighting pipeline progress and upcoming milestones.
Key Financial Metrics
Key Facts
- Q3 2026 total net product revenue $259.7M, up 52% YoY from $171.0M
- AUVELITY net product sales $207.6M, up 53% YoY
- SUNOSI net product revenue $48.2M, up 47% YoY (includes $8.5M milestone revenue)
- SYMBRAVO net product sales $3.9M, up 88% YoY
- Net loss narrowed to $12.9M ($0.25 per share) from $47.2M ($0.94 per share) YoY
- Cash and cash equivalents $313.9M at September 30, 2026
- AUVELITY prescriptions ~302,000 in Q3 2026, up 40% YoY and 14% QoQ
- New-to-brand prescriptions for AUVELITY increased 44% YoY and 21% QoQ
- AUVELITY prescriptions among patients 65+ increased 211% YoY and 99% QoQ
- SUNOSI prescriptions ~64,400, up 15% YoY
- SYMBRAVO prescriptions ~25,000, up 382% YoY
- SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated in August 2026
- ENGAGE Phase 3 trial of solriamfetol in binge eating disorder reached target enrollment; topline results expected Q1 2027
- AXS-12 NDA for cataplexy in narcolepsy under FDA review; PDUFA date May 1, 2027
- EPS of $(0.25) beat consensus estimate of $(0.64) by 60.9%
- Revenue of $259.7M beat consensus estimate of $249.2M by 4.2%
Financial Impact
Revenue growth of 52% YoY to $259.7M, net loss improvement of 73% YoY to $12.9M, EPS beat of $0.39 vs consensus
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| AUVELITY | $207.6M | +52.5% |
| SUNOSI | $48.2M | +47.0% |
| SYMBRAVO | $3.9M | +85.7% |
Risk Factors
- SG&A expenses remain high at $203.1M, up 35% YoY, as commercialization costs continue
- Cash burn continues; cash decreased from $322.9M at Dec 2025 to $313.9M at Sep 2026
- Pipeline reliance on clinical trial outcomes; ENGAGE, FOCUS-2/3, SUMMIT, and SUSTAIN results are binary events
- AXS-12 PDUFA decision on May 1, 2027 carries regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-442628 |
| Document: axsm-20261102.htm | 0001193125-26-442628 |
| Document: axsm-ex99_2.htm | 0001193125-26-442628 |
| Document: 0001193125-26-442628-index-headers.html | 0001193125-26-442628 |
| Document: 0001193125-26-442628-index.html | 0001193125-26-442628 |
| Document: 0001193125-26-442628.txt | 0001193125-26-442628 |
| 8-K Data (Synthetic) | 0001193125-26-442628 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers